Spinal Cord Burst Stimulation vs Placebo Stimulation for Patients With Chronic Radicular Pain After Lumbar Spine Surgery.
Simon Thomson, Jan Willem Kallewaard, Kliment Gatzinsky
https://pubmed.ncbi.nlm.nih.gov/36917057/Actively Recruiting
Led by Sahlgrenska University Hospital · Updated on 2025-12-02
50
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are evaluating spinal cord stimulation SCS as a treatment for persistent neuropathic leg pain that continues after lumbar spinal surgery and does not improve with medication or other conservative treatments. This study is a multicenter, double-blind, randomized, sham-controlled trial designed to compare the long-term effects of active, subthreshold SCS versus no stimulation placebo on reducing neuropathic leg pain in patients with persistent spinal pain syndrome type 2 PSPS2. The study aims to assess not only pain reduction but also quality of life, physical functioning, sleep quality, return to work, and medication use. Participants who respond positively to a two-week SCS test trial will have a non-rechargeable Boston Alpha Prime SCS system implanted. After initial electrode implantation and a trial phase, those with adequate pain relief will receive a permanent implant. The study includes a four-week optimization period followed by a six-month randomized crossover phase where patients receive either active subthreshold stimulation or sham stimulation for three months each. Then, participants will use their preferred stimulation form for an additional six months. Both patients and physicians remain unaware of the stimulation status during the blinded phases, with only a research nurse managing programming. During the study, participants will complete questionnaires before implantation and at regular follow-ups at 3, 6, and 12 months. Researchers will monitor changes in leg pain intensity using the Numeric Rating Scale NRS and evaluate secondary outcomes such as quality of life and physical function. After completing the 12-month follow-up, blinding will be lifted, and participants may choose any available stimulation form. The total participation duration is approximately one year, including surgery, stimulation phases, and follow-up assessments.
CONDITIONS
Placebo Effect In Spinal Cord Electrical Stimulation for Pain
K
Kliment Gatzinsky, MD, PhD
J
Jan Willem Kallewaard, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sahlgrenska University Hospital
Lead Sponsor
Rijnstate Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - Initial surgery and recovery period
Participants undergo surgery to implant electrode(s) into the epidural space for spinal cord stimulation.
1 surgical visit plus recovery period
Duration - 2 weeks
Participants undergo a 2-week trial phase with external stimulation to determine if adequate pain relief is achieved.
Trial phase with external device; visits not specifically detailed
Duration - Permanent implant surgery and recovery
Participants who respond positively to the trial phase receive implantation of a permanent pulse generator under the skin.
1 surgical visit plus recovery period
Duration - 12 months
Participants receive either active subthreshold spinal cord stimulation or sham stimulation in a double-blind, randomized crossover design with a 4-week optimization period followed by two 3-month stimulation periods and a final 6-month period using the preferred stimulation.
Routine follow-up visits at 3, 6, and 12 months
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Simon Thomson, Jan Willem Kallewaard, Kliment Gatzinsky
https://pubmed.ncbi.nlm.nih.gov/36917057/José Paz-Solís, Simon Thomson, Roshini Jain...
https://pubmed.ncbi.nlm.nih.gov/35041592/Simon J Thomson, Moein Tavakkolizadeh, Sarah Love-Jones...
https://pubmed.ncbi.nlm.nih.gov/29220121/Timothy R Deer, Nagy Mekhail, David Provenzano...
https://pubmed.ncbi.nlm.nih.gov/25112889/Timothy Deer, Christopher Gilligan, Steven Falowski...
https://pubmed.ncbi.nlm.nih.gov/37642628/Yilong Zheng, Christopher Weiyang Liu, Diana Xin Hui Chan...
https://pubmed.ncbi.nlm.nih.gov/37436342/Krishna Kumar, Rod S Taylor, Line Jacques...
https://pubmed.ncbi.nlm.nih.gov/17845835/Scott L Parker, Stephen K Mendenhall, Saniya S Godil...
https://pubmed.ncbi.nlm.nih.gov/25694267/Sozaburo Hara, Hege Andresen, Ole Solheim...
https://pubmed.ncbi.nlm.nih.gov/36255427/Richard B North, David H Kidd, Farrokh Farrokhi...
https://pubmed.ncbi.nlm.nih.gov/15617591/Sahlgrenska University Hospital
Lead Sponsor
Rijnstate Hospital
Collaborating Sponsor